Antiepileptic therapy algorithms in patients with primary and metastatic brain tumors

Abstract

Up to date the brain tumors incidence keeps growing worldwide. Epilepsy and epileptic seizures are one of the most common clinical features of brain tumors. The aim of the study was to invent the algorithms antiepileptic treatment of patients with primary and metastatic brain tumors based on literature data. We searched eLIBRARY, PubMed databases by keywords. We concluded, that preventive antiepileptic drugs administration in patients with primary or metastatic brain lesions does not lower the risk of acute symptomatic postoperative seizures or epilepsy incidence, and therefore should not be recommended. Experts’ opinion states that in patients with brain tumors even one unprovoked seizure makes it feasible to initiate antiepileptic drugs therapy as soon as possible. In case of two or more unprovoked episodes (with over 24 hours difference) the diagnosis of “epilepsy” is legitimate and antiepileptic therapy should be started. The treating physician’s choice of antiepileptic therapy is based on type of seizures, age and sex of the patient, the comorbidity and potential antiepileptic drugs pharmacokinetic interactions with other drugs (including chemotherapy), in particular, one should avoid the use of liver microsomal-inducing antiepileptic drugs. The presented algorithms provide the decision-making guidelines in case of intraoperative focal seizures, acute symptomatic seizures and status epilepticus occurrence in early postoperative period.

Keywords

acute symptomatic seizures / antiepileptic drugs usage algorithms / chemotherapy / epilepsy / gliomas / primary and metastatic tumors / status epilepticus / unprovoked epileptic seizure

References

[1] Prokudin MYu, Odinak MM, Litvinenko IV, et al. Clinical and morphological risk factors for epilepsy in patients with glial and metastatic brain tumors. The Korsakov’s Journal of Neurology and Psychiatry. 2020;120(11):22–28. (In Russ.) DOI: 10.17116/jnevro202012011122

[2] Прокудин М.Ю., Одинак М.М., Литвиненко И.В., и др. Клинико-морфологические факторы риска развития эпилепсии у больных с глиальными и метастатическими опухолями головного мозга // Журнал неврологии и психиатрии им. С.С. Корсакова. 2020. Т. 120, № 11. С. 22–28. DOI: 10.17116/jnevro202012011122

[3] Dewan MC, Thompson RC, Kalkanis SN, et al. Prophylactic antiepileptic drug administration following brain tumor resection: results of a recent AANS/CNS Section on Tumors survey. J Neurosurg. 2017;126(6):1772–1778. DOI: 10.3171/2016.4.JNS16245

[4] Dewan M.C., Thompson R.C., Kalkanis S.N., et al. Prophylactic antiepileptic drug administration following brain tumor resection: results of a recent AANS/CNS Section on Tumors survey // J. Neurosurg. 2017. Vol. 126, No. 6. P. 1772–1778. DOI: 10.3171/2016.4. JNS16245

[5] Kobyakov GL, Bekyashev AKh, Golanov AV, et al. Practicalrecommendations for drug treatment of primary tumorscentral nervous system. Malignant tumours. 2017;7(3S2):77–92. (In Russ.) DOI: 77-9210.18027/2224-5057-2017-7-3s2-77-92

[6] Кобяков Г.Л., Бекяшев А.Х., Голанов А.В., и др. Практические рекомендации по лекарственному лечению первичных опухолей центральной нервной системы // Злокачественные опухоли. 2017. Т. 7, № 3S2. С. 77–92. DOI: 10.18027/2224-5057-2017-7-3s2-77-92

[7] Ulitin AJu, Macko MV, Kobjakov GL, et al. Practicalrecommendations for drug treatment of primary tumors of the central nervous system. Malignant tumours. 2022;12(3s2):113–140. (In Russ.) DOI: 10.18027/2224-5057-2022-12-3s2-113-140

[8] Улитин А.Ю., Мацко М.В., Кобяков Г.Л., и др. Практические рекомендации по лекарственному лечению первичных опухолей центральной нервной системы // Злокачественные опухоли. 2022. Т. 12, № 3s2. С. 113–140. DOI: 10.18027/2224-5057-2022-12-3s2-113-140

[9] Walbert T, Harrison RA, Schiff D, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021;23(11):1835–1844. DOI: 10.1093/neuonc/noab152

[10] Walbert T., Harrison R.A., Schiff D., et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors // Neuro Oncol. 2021. Vol. 23, No. 11. P. 1835–1844. DOI: 10.1093/neuonc/noab152

[11] Ansari SF, Bohnstedt BN, Perkins SM, et al. Efficacy of postoperative seizure prophylaxis in intra-axial brain tumor resections. J Neurooncol. 2014;118(1):117–122. DOI: 10.1007/s11060-014-1402-9

[12] Ansari S.F., Bohnstedt B.N., Perkins S.M., et al. Efficacy of postoperative seizure prophylaxis in intra-axial brain tumor resections // J. Neurooncol. 2014. Vol. 118, No. 1. Р. 117–122. DOI: 10.1007/s11060-014-1402-9

[13] Clinical recommendations of the Ministry of Health of the Russian Federation of 16 August 2022. “Epilepsiya i epilepticheskii status u vzroslykh i detei”. (In Russ.) Available from: https://cr.minzdrav.gov.ru/schema/741_1?ysclid=lid2g3qipu593990056 (accessed 07.06.2023.).

[14] Эпилепсия и эпилептический статус у взрослых и детей. Клинические рекомендации. Утв. Министерством здравоохранения Российской Федерации 16.08.22. Доступен по: https://cr.minzdrav.gov.ru/schema/741_1?ysclid=lid2g3qipu593990056 (дата обращения 07.06.2023.).

[15] Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–482. DOI: 10.1111/epi.12550

[16] Fisher R.S., Acevedo C., Arzimanoglou A., et al. ILAE official report: a practical clinical definition of epilepsy // Epilepsia. 2014. Vol. 55, No. 4. P. 475–482. DOI: 10.1111/epi.12550

[17] Hesdorffer DC, Benn EK, Cascino GD, et al. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia. 2009;50(5):1102–1108. DOI: 10.1111/j.1528-1167.2008.01945.x

[18] Hesdorffer D.C., Benn E.K., Cascino G.D., et al. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure // Epilepsia. 2009. Vol. 50, No 5. P. 1102–1108. DOI: 10.1111/j.1528-1167.2008.01945.x

[19] Liang S, Fan X, Zhao M, et al. Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma-related epilepsy. Cancer Med. 2019;8(10):4527–4535. DOI: 10.1002/cam4.2362

[20] Liang S., Fan X., Zhao M., et al. Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma-related epilepsy // Cancer Med. 2019. Vol. 8, No. 10. P. 4527–4535. DOI: 10.1002/cam4.2362

[21] Prokudin MYu, Martynov BV, Yakovenko AI, et al. The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas. Epilepsy and paroxysmal conditions. 2022;14(2): 204–213. (In Russ.) DOI: 10.17749/2077-8333/epi.par.con.2022.118

[22] Прокудин М.Ю., Мартынов Б.В., Яковенко А.И., и др. Роль экспрессии глутамин-синтетазы и транспортера цистин/глутамата (SLC7A11, xCT) в патогенезе развития эпилепсии у пациентов с супратенториальными глиомами головного мозга // Эпилепсия и пароксизмальные состояния. 2022. Т. 14, № 2. С. 204–213. DOI: 10.17749/2077-8333/epi.par.con.2022.118

[23] Villikka K, Kivistö KT, Mäenpää H, et al. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther. 1999;66(6): 589–593. DOI: 10.1053/cp.1999.v66.103403001

[24] Villikka K., Kivistö K., Mäenpää H., et al. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors // Clin. Pharmacol. Ther. 1999. Vol. 66, No. 6. P. 589–593. DOI: 10.1053/cp.1999.v66.103403001

[25] Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77(12):1156–116. DOI: 10.1212/WNL.0b013e31822f02e1

[26] Weller M., Gorlia T., Cairncross J.G., et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma // Neurology. 2011. Vol. 77, No. 12. P. 1156–1164. DOI: 10.1212/WNL.0b013e31822f02e1

[27] Kerkhof M, Dielemans JC, van Breemen MS, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol. 2013;15(7):961–967. DOI: 10.1093/neuonc/not057

[28] Kerkhof M., Dielemans J.C., van Breemen M.S., et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme // Neuro Oncol. 2013. Vol. 15, No 7. P. 961–967. DOI: 10.1093/neuonc/not057

[29] Guthrie GD, Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg. 2013;118(4):859–865. DOI: 10.3171/2012.10.JNS12169

[30] Guthrie G.D., Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme // J. Neurosurg. 2013. Vol. 118, No. 4. P. 859–865. DOI: 10.3171/2012.10.JNS12169

[31] Vecht CJ, Kerkhof M, Duran-Pena A. Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist. 2014;19(7):751–759. DOI: 10.1634/theoncologist.2014-0060

[32] Vecht C.J., Kerkhof M., Duran-Pena A. Seizure prognosis in brain tumors: new insights and evidence-based management // Oncologist. 2014. Vol. 19, No. 7. P. 751–759. DOI: 10.1634/theoncologist.2014-0060

[33] Happold C, Gorlia T, Chinot O, et al. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. J Clin Oncol. 2016;34(7):731–739. DOI: 10.1200/JCO.2015.63.6563

[34] Happold C., Gorlia T., Chinot O., et al. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma // J. Clin. Oncol. 2016. Vol. 34, No. 7. P. 731–739. DOI: 10.1200/JCO.2015.63.6563

[35] van der Meer PB, Dirven L, Fiocco M, et al. First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. Epilepsia. 2021;62(5):1119–1129. DOI: 10.1111/epi.16880

[36] Van der Meer P.B., Dirven L., Fiocco M., et al. First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid // Epilepsia. 2021. Vol. 62, No. 5. P. 1119–1129. DOI: 10.1111/epi.16880

[37] Kumar R, Vidaurre J, Gedela S. Valproic Acid-Induced Coagulopathy. Pediatr. Neurol. 2019;98:25–30. DOI: 10.1016/j.pediatrneurol.2019.04.019

[38] Kumar R., Vidaurre J., Gedela S. Valproic Acid-Induced Coagulopathy // Pediatr. Neurol. 2019. Vol. 98. P. 25–30. DOI: 10.1016/j.pediatrneurol.2019.04.019

[39] Yagi C, Tatsuoka J, Sano E, et al. Antitumor effects of antiepileptic drugs in malignant glioma cells. Oncol Rep. 2022;48(6):216. DOI: 10.3892/or.2022.8431

[40] Yagi C., Tatsuoka J., Sano E., et al. Antitumor effects of antiepileptic drugs in malignant glioma cells // Oncol. Rep. 2022. Vol. 48, No. 6. P. 216. DOI: 10.3892/or.2022.8431

[41] Correia CE, Umemura Y, Flynn JR, et al. Pharmacoresistant seizures and IDH mutation in low-grade gliomas. Neurooncol Adv. 2021;3(1): vdab146. DOI: 10.1093/noajnl/vdab146

[42] Correia C.E., Umemura Y., Flynn J.R., et al. Pharmacoresistant seizures and IDH mutation in low-grade gliomas // Neurooncol. Adv. 2021. Vol. 3, No. 1. P. vdab146. DOI: 10.1093/noajnl/vdab146

[43] Prokudin MYu, Martynov BV, Svistov DV, et al. Genetic biomarkers of glial brain tumors: idh1 and idh2 mutations. SSiberian Journal of Oncology. 2020;19(4):59–66. (In Russ.) DOI: 10.21294/1814-4861-2020-19-4-59-66

[44] Прокудин М.Ю., Мартынов Б.В., Свистов Д.В., и др. Генетические биологические маркеры глиальных опухолей головного мозга: мутации в генах изоцитратдегидрогеназ 1 и 2 // Сибирский онкологический журнал. 2020. Т. 19, № 4. С. 59–66. DOI: 10.21294/1814-4861-2020-19-4-59-66

[45] Jutras G, Bélanger K, Letarte N, et al. Procarbazine, lomustine and vincristine toxicity in low-grade gliomas. Curr Oncol. 2018;25(1): e33–e39. DOI: 10.3747/co.25.3680

[46] Jutras G., Bélanger K., Letarte N., et al. Procarbazine, lomustine and vincristine toxicity in low-grade gliomas // Curr. Oncol. 2018. Vol. 25, No. 1. P. e33–e39. DOI: 10.3747/co.25.3680

[47] Irfan N, Samuel E, Rafi Ranjha F, et al. Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma — Retrospective Review. Cureus. 2020;12(10):e11070. DOI: 10.7759/cureus.11070

[48] Irfan N., Samuel E., Rafi Ranjha F., et al. Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma — Retrospective Review // Cureus. 2020. Vol. 12, No. 10. P. e11070. DOI: 10.7759/cureus.11070

[49] King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6(2):162–176. DOI: 10.1634/theoncologist.6-2-162

[50] King P.D., Perry M.C. Hepatotoxicity of chemotherapy // Oncologist. 2001. Vol. 6, No. 2. P. 162–176. DOI: 10.1634/theoncologist.6-2-162

[51] el Saghir NS, Hawkins KA. Hepatotoxicity following vincristine therapy. Cancer. 1984;54(9):2006–2008. DOI: 10.1002/1097-0142(19841101)54:9<2006::aid-cncr2820540937>3.0.co;2-f

[52] еl Saghir N.S., Hawkins K.A. Hepatotoxicity following vincristine therapy // Cancer. 1984. Vol. 54, No. 9. P. 2006–2008. DOI: 10.1002/1097-0142(19841101)54:9<2006::aid-cncr2820540937>3.0.co;2-f

[53] Horbinski C, Nabors LB, Portnow J, et al. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw. 2023;21(1):12–20. DOI: 10.6004/jnccn.2023.0002

[54] Horbinski C., Nabors L.B., Portnow J., et al. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022 // J. Natl Compr. Canc. Netw. 2023. Vol. 21, No. 1. P. 12–20. DOI: 10.6004/jnccn.2023.0002

[55] Ortiz R, Perazzoli G, Cabeza L, et al. Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Curr Neuropharmacol. 2021;19(4):513–537. DOI: 10.2174/1570159X18666200626204005

[56] Ortiz R., Perazzoli G., Cabeza L., et al. Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications // Curr. Neuropharmacol. 2021. Vol. 19, No. 4. P. 513–537. DOI: 10.2174/1570159X18666200626204005

[57] Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. DOI: 10.1016/S1470-2045(09)70025-7

[58] Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial // Lancet Oncol. 2009. Vol. 10, No. 5. P. 459–466. DOI: 10.1016/s1470-2045(09)70025-7

[59] Cucchiara F, Ferraro S, Luci G, Bocci G. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. Pharmacol Res. 2022;175:105976. DOI: 10.1016/j.phrs.2021.105976

[60] Cucchiara F., Ferraro S., Luci G., Bocci G. Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data // Pharmacol. Res. 2022. Vol. 175. P. 105976. DOI: 10.1016/j.phrs.2021.105976

[61] Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943–953. DOI: 10.1016/S1470-2045(14)70314-6

[62] Taal W., Oosterkamp H.M., Walenkamp A.M., et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial // Lancet Oncol. 2014. Vol. 15, No. 9. P. 943–953. DOI: 10.1016/S1470-2045(14)70314-6

[63] Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–4740. DOI: 10.1200/JCO.2008.19.8721

[64] Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma // J. Clin. Oncol. 2009. Vol. 27, No. 28. P. 4733–4740. DOI: 10.1200/JCO.2008.19.8721

[65] Rogers LR. Chemotherapy and immunotherapy of brain tumors: what the epileptologist must know. Epilepsia. 2013;54(Suppl 9):105–108. DOI: 10.1111/epi.12453

[66] Rogers L.R. Chemotherapy and immunotherapy of brain tumors: What the epileptologist must know // Epilepsia. 2013. Vol. 54, Suppl. 9. P. 105–108. DOI: 10.1111/epi.12453

[67] Berg AK, Buckner JC, Galanis E, et al. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure. J Clin Pharmacol. 2015;55(11):1303–1312. DOI: 10.1002/jcph.543

[68] Berg A.K., Buckner J.C., Galanis E., et al. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure // J. Clin. Pharmacol. 2015. Vol. 55, No. 11. P. 1303–1312. DOI: 10.1002/jcph.543

[69] Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–4729. DOI: 10.1200/JCO.2007.12.2440

[70] Vredenburgh J.J., Desjardins A., Herndon J.E. 2nd, et al. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme // J. Clin. Oncol. 2007. Vol. 25, No. 30. P. 4722–4729. DOI: 10.1200/JCO.2007.12.2440

[71] Molenaar-Kuijsten L, Van Balen DEM, Beijnen JH, et al. A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs. Front Pharmacol. 2021;12:670862. DOI: 10.3389/fphar.2021.670862

[72] Molenaar-Kuijsten L., Van Balen D.E.M., Beijnen J.H., et al. A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs // Front. Pharmacol. 2021. Vol. 12. P. 670862. DOI: 10.3389/fphar.2021.670862

[73] Moon J, Kim MS, Kim YZ, et al. The Korean Society for Neuro-Oncology (KSNO) Guideline for Antiepileptic Drug Usage of Brain Tumor: Version 2021.1. Brain Tumor Res Treat. 2021;9(1):9–15. DOI: 10.14791/btrt.2021.9.e7

[74] Moon J., Kim M.S., Kim Y.Z., et al. The Korean Society for Neuro-Oncology (KSNO) Guideline for Antiepileptic Drug Usage of Brain Tumor: Version 2021.1 // Brain Tumor Res. Treat. 2021. Vol. 9, No. 1. P. 9–15. DOI: 10.14791/btrt.2021.9.e7

[75] Aver’yanov DA, Lukash AA, Prokudin MYu, et al. Non-convulsive epileptic seizure in patient with delayed awakening after supratentorial tumor removal. Russian Journal of Anаеsthesiology and Reanimatology. 2016;61(2):143–146. (In Russ.). DOI: 10.18821/0201-7563-2016-61-2-143-146

[76] Аверьянов Д.А., Лукаш А.А., Прокудин М.Ю., и др. Бессудорожный эпилептический приступ при отсроченном пробуждении пациента после удаления новообразования супратенториальной локализации // Анестезиология и реаниматология. 2016. Т. 61, № 2. С. 143–146. DOI: 10.18821/0201-7563-2016-61-2-143-146

RIGHTS & PERMISSIONS

Eco-Vector